• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Biomea Fusion Inc. (Amendment)

    2/14/24 4:21:50 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMEA alert in real time by email
    SC 13G/A 1 tm242424d11_sc13ga.htm SC 13G/A

     

     

    SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    Biomea Fusion, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    09077A106

     

    (CUSIP Number)

     

    December 31, 2023

     
      (Date of Event which Requires Filing of this Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No.  09077A106

     

    1 NAMES OF REPORTING PERSONS

    Baker Bros. Advisors LP
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) ¨
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER

       
    2,108,949
    6 SHARED VOTING POWER

       
    -0-
    7 SOLE DISPOSITIVE POWER

       
    2,108,949
    8 SHARED DISPOSITIVE POWER

       
    -0-

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

       
    2,108,949
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)
      ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

       
    5.9% (1)
    12 TYPE OF REPORTING PERSON (See Instructions)

       
    IA, PN

     

      (1) Based on 35,705,786 shares of Common Stock (“Common Stock”) of Biomea Fusion, Inc. (the “Issuer”) outstanding as of October 23, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on October 30, 2023.

     

     

     

     

     

    CUSIP No.  09077A106

     

    1 NAMES OF REPORTING PERSONS

    Baker Bros. Advisors (GP) LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) ¨
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER

       
    2,108,949
    6 SHARED VOTING POWER

       
    -0-
    7 SOLE DISPOSITIVE POWER

       
    2,108,949
    8 SHARED DISPOSITIVE POWER

       
    -0-

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

       
    2,108,949
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)
      ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

       
    5.9% (1)
    12 TYPE OF REPORTING PERSON (See Instructions)

       
    HC, OO

     

      (1) Based on 35,705,786 shares of Common Stock of the Issuer outstanding as of October 23, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on October 30, 2023.

     

     

     

     

    CUSIP No.  09077A106

     

    1 NAMES OF REPORTING PERSONS

    Felix J. Baker
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) ¨
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER

       
    2,108,949
    6 SHARED VOTING POWER

       
    -0-
    7 SOLE DISPOSITIVE POWER

       
    2,108,949
    8 SHARED DISPOSITIVE POWER

       
    -0-

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

       
    2,108,949
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)
      ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

       
    5.9% (1)
    12 TYPE OF REPORTING PERSON (See Instructions)

       
    IN, HC

     

      (1) Based on 35,705,786 shares of Common Stock of the Issuer outstanding as of October 23, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on October 30, 2023.

     

     

     

     

    CUSIP No.  09077A106

     

    1 NAMES OF REPORTING PERSONS

    Julian C. Baker
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) ¨
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER

       
    2,108,949
    6 SHARED VOTING POWER

       
    -0-
    7 SOLE DISPOSITIVE POWER

       
    2,108,949
    8 SHARED DISPOSITIVE POWER

       
    -0-

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

       
    2,108,949
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)
      ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

       
    5.9% (1)
    12 TYPE OF REPORTING PERSON (See Instructions)

       
    IN, HC

     

      (1) Based on 35,705,786 shares of Common Stock of the Issuer outstanding as of October 23, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on October 30, 2023.

     

     

     

     

    Amendment No. 1 to Schedule 13G

     

    This Amendment No. 1 to Schedule 13G amends the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker and Felix J. Baker (collectively, the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

     

    Item 1(a) Name of Issuer:

     

    Biomea Fusion, Inc. (the “Issuer”)

     

    Item 1(b) Address of Issuer’s Principal Executive Offices:

     

    900 Middlefield Road, 4th Floor

     

    Redwood City, CA 94063

     

    Item 2(a) Name of Person Filing:

     

    This Amendment No. 1 is being filed jointly by the Reporting Persons.

     

    Item 2(b) Address of Principal Business Office or, if None, Residence:

     

    The business address of each of the Reporting Persons is:

     

    c/o Baker Bros. Advisors LP

     

    860 Washington Street, 3rd Floor

     

    New York, NY 10014

     

    (212) 339-5690

     

    Item 2(c) Citizenship:

     

    The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

     

    Item 2(d) Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (“Common Stock”).

     

    Item 2(e) CUSIP Number:

     

    09077A106

     

     

     

     

    Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Exchange Act.

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Exchange Act.

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act.

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940.

     

    (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

     

    (i)  ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.

     

    (j)  ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    Item 4 Ownership:

     

    Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 1 are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock directly held by each of Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”) which may be deemed to be indirectly beneficially owned by the Reporting Persons.

     

    The information set forth below is based on 35,705,786 shares of Common Stock outstanding as of October 23, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on October 30, 2023. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

     

     

     

     

      Holder  Number of Shares of Common
    Stock we own or have the right
    to acquire within 60 days
       Percent of Class
    Outstanding
     
      667, L.P.   176,858    0.5%
      Baker Brothers Life Sciences, L.P.   1,932,091    5.4%
      Total   2,108,949    5.9%

     

    The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.

     

    The Adviser GP is the sole general partner of the Adviser. Pursuant to the management agreements, as amended, among the Adviser, Life Sciences and 667 and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

     

    Item 5 Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨. N/A

     

    Item 6 Ownership of More than Five Percent on Behalf of Another Person:

     

    N/A

     

    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    The information in Item 4 is incorporated herein by reference.

     

    Item 8 Identification and Classification of Members of the Group:

     

    N/A

     

    Item 9 Notice of Dissolution of Group:

     

    N/A

     

    Item 10 Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 14, 2024

     

     

    BAKER BROS. ADVISORS LP

     

    By: Baker Bros. Advisors (GP) LLC, its general partner

         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      BAKER BROS. ADVISORS (GP) LLC
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President      

     

        /s/ Julian C. Baker
        Julian C. Baker
     
        /s/ Felix J. Baker
        Felix J. Baker

     

     

     

    Get the next $BMEA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BMEA

    DatePrice TargetRatingAnalyst
    6/3/2025$7.00Overweight
    Piper Sandler
    10/9/2024$128.00Buy
    Edward Jones
    9/27/2024$18.00Neutral → Buy
    Rodman & Renshaw
    9/27/2024$54.00Hold → Buy
    Truist
    8/29/2024$25.00Overweight
    CapitalOne
    6/11/2024Buy → Hold
    Truist
    6/7/2024$30.00 → $5.00Overweight → Equal Weight
    Barclays
    4/2/2024$51.00 → $14.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $BMEA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Biomea Fusion with a new price target

      Piper Sandler resumed coverage of Biomea Fusion with a rating of Overweight and set a new price target of $7.00

      6/3/25 7:31:50 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edward Jones initiated coverage on Biomea Fusion with a new price target

      Edward Jones initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $128.00

      10/9/24 8:20:08 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion upgraded by Rodman & Renshaw with a new price target

      Rodman & Renshaw upgraded Biomea Fusion from Neutral to Buy and set a new price target of $18.00

      9/27/24 7:30:48 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hitchcock Michael J.M. bought $100,600 worth of shares (10,000 units at $10.06), increasing direct ownership by 200% to 15,000 units (SEC Form 4)

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      10/1/24 4:30:12 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Valle Franco was granted 4,448 shares and bought $55,361 worth of shares (12,509 units at $4.43), increasing direct ownership by 66% to 42,500 units (SEC Form 4)

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      6/12/24 4:30:07 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Financials

    Live finance-specific insights

    See more
    • Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

      Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 with statistical significance, after only 12 weeks of dosing icovamenib with 100 mgIcovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company

      12/17/24 8:10:00 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

      REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from COVALENT-111, the company's Phase II trial of icovamenib in patients with type 2 diabetes. Conference Call and Webcast Details Webcast of Biomea's investor update on Tuesday, December 17, 2024, at 8:00 am EST will be available to reg

      12/16/24 6:15:01 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

      Preliminary data supports BMF-500's potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and tolerability profile, with no dose-limiting toxicities observed across all dose levelsPharmacokinetic and pharmacodynamic data confirmed on-target FMS-like tyrosine kinase 3 (FLT3) inhibition, demonstrating dose-proportional activity and good compartmental penetrationPreliminary Phase I data for BMF-500 in R/R acute leukemia patients with FLT3 gene mutations having failed gilteritinib indicated clinical activity with evidence of responses, including a first complete response with incomplete hematologic recove

      12/9/24 4:01:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Faust Elizabeth

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      6/13/25 4:15:20 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ray Sumita

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      6/13/25 4:15:17 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aguiar Eric

      4 - Biomea Fusion, Inc. (0001840439) (Issuer)

      6/13/25 4:15:18 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

      In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide aloneIcovamenib promoted healthy myotube morphology and diminished drug-induced atrophy in ex vivo 3D-engineered human myotube culturesIn severely insulin-deficient patients from the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide at Week 26, three weeks after last dose SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea or Biomea Fusion) (NASDAQ:

      6/23/25 7:00:00 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

      Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025; with Phase I study initiation in obese, otherwise healthy volunteers anticipated late 2025 REDWOOD CITY, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced new preclinical findings from a 28-day weight loss study in obese non-human primates evaluating BMF-650, the Company's investigational, next-generation oral

      6/18/25 7:00:00 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Announces Pricing of Public Offering of Securities

      REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19,450,000 shares of its common stock and accompanying warrants to purchase an aggregate of 19,450,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 550,000 shares of its common stock and accompanying warrants to purchase an aggregate of 550,000 shares of common stock (or pre-funded warrants in lieu thereof), at an e

      6/17/25 11:15:12 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Biomea Fusion Inc.

      SCHEDULE 13G - Biomea Fusion, Inc. (0001840439) (Subject)

      6/25/25 10:17:57 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Biomea Fusion Inc.

      8-K - Biomea Fusion, Inc. (0001840439) (Filer)

      6/20/25 5:13:37 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Biomea Fusion Inc.

      8-K - Biomea Fusion, Inc. (0001840439) (Filer)

      6/18/25 5:30:11 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Leadership Updates

    Live Leadership Updates

    See more
    • Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

      Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapyBiomea's next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities are either being partnered or closed REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 202

      5/5/25 4:05:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

      Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, reported

      3/31/25 4:10:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Announces Leadership Transition

      Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) --  Biomea Fusion, Inc. ("Biomea," or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential developing a novel therapy for diabetes. Specifically, Mick Hitchcock, a current board member since 2021, will succeed Thomas Butler as interim Chief Executive Officer. The change is effective immediately. "As a long-time member of Biomea's Board, I've had the privilege

      3/25/25 7:00:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMEA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

      SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

      11/12/24 12:31:45 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

      SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

      7/10/24 6:39:58 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Biomea Fusion Inc.

      SC 13G - Biomea Fusion, Inc. (0001840439) (Subject)

      4/10/24 9:45:50 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care